[1] |
Liang J, Zhu J, Wang M, et al. Evaluation of AGP fucosylation as a marker for hepatocellular carcinoma of three different etiologies. Sci Rep 2019; 9(1): 11580. doi: 10.1038/s41598-019-48043-1.
doi: 10.1038/s41598-019-48043-1
|
[2] |
Skill NJ, Butler J, O’Brien DC, et al. Financial burden of liver transplant vs. resection for hepatocellular carcinoma. Transplant Proc 2019; 51(6):1907-12. doi: 10.1016/j.transproceed.2019.04.026.
doi: 10.1016/j.transproceed.2019.04.026
|
[3] |
Ji D, Hu G, Zhang X, et al. Long non-coding RNA DSCAM-AS 1 accelerates the progression of hepatocellular carcinoma via sponging miR-338-3p. Am J Transl Res 2019; 11(7):4290-302.
|
[4] |
Meyerovich G, Goykhman Y, Nakache R, et al. Resection vs. transplant listing for hepatocellular carcinoma: an intention-to-treat analysis. Transplant Proc 2019; 51(6):1867-73. doi: 10.1016/j.transproceed.2019.02.030.
doi: 10.1016/j.transproceed.2019.02.030
|
[5] |
Huang FY, Wong DK, Tsui VW, et al. Targeted genomic profiling identifies frequent deleterious mutations in FAT4 and TP 53 genes in HBV-associated hepatocellular carcinoma. BMC cancer 2019; 19(1): 789. doi: 10.1186/s12885-019-6002-9.
doi: 10.1186/s12885-019-6002-9
|
[6] |
Rocha FV, Farias RL, Lima MA, et al. Computational studies, design and synthesis of Pd(II)-based complexes: allosteric inhibitors of the human topoisomerase-IIα. J Inorg Biochem 2019; 199:110725. doi: 10.1016/j.jinorgbio.2019.110725.
doi: 10.1016/j.jinorgbio.2019.110725
|
[7] |
Zeng S, Liu A, Dai L, et al. Prognostic value of TOP2A in bladder urothelial carcinoma and potential molecular mechanisms. BMC cancer 2019; 19(1): 604. doi: 10.1186/s12885-019-5814-y.
doi: 10.1186/s12885-019-5814-y
pmid: 31216997
|
[8] |
Nuncia-Cantarero M, Martinez-Canales S, Andrés-Pretel F, et al. Functional transcriptomic annotation and protein-protein interaction network analysis identify NEK2, BIRC5, and TOP2A as potential targets in obese patients with luminal A breast cancer. Breast Cancer Res Treat 2018; 168(3):613-23. doi: 10.1007/s10549-017-4652-3.
doi: 10.1007/s10549-017-4652-3
|
[9] |
Ghisoni E, Maggiorotto F, Borella F, et al. TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers. J Ovarian Res 2019; 12(1): 17. doi: 10.1186/s13048-019-0492-6.
doi: 10.1186/s13048-019-0492-6
|
[10] |
Connell LC, Harding JJ, Shia J. Combined intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Chin Clin Oncol 2016; 5(5): 66. doi: 10.21037/cco.2016.10.02.
doi: 10.21037/cco.2016.10.02
|
[11] |
Sun Q, Yao GD, Song XY, et al. Autophagy antagonizes apoptosis induced by flavan enantiomers from Daphne giraldii in hepatic carcinoma cells in vitro. Eur J Med Chem 2017; 133:1-10. doi: 10.1016/j.ejmech.2017.03.072.
doi: 10.1016/j.ejmech.2017.03.072
|
[12] |
Iwanaga T. Studies on cases of spontaneous regression of cancer in Japan in 2011, and of hepatic carcinoma, lung cancer and pulmonary metastases in the world between 2006 and 2011. Gan To Kagaku Ryoho 2013; 40 (11):1475-87.
|
[13] |
Zhou Z, Li Y, Hao H, et al. Screening hub genes as prognostic biomarkers of hepatocellular carcinoma by bioinformatics analysis. Cell Transplant 2019; 28(1_suppl):76S-86S. doi: 10.1177/0963689719893950.
doi: 10.1177/0963689719893950
|
[14] |
Chen JR, Chien HP, Chen KS, et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer. Medicine (Baltimore) 2017; 96(2): e5582. doi: 10.1097/MD.0000000000005582.
doi: 10.1097/MD.0000000000005582
|
[15] |
Almeida D, Renê Gerhard, Dina Leitão, et al. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer. Pathol Res Pract 2014; 210(10):675-9. doi: 10.1016/j.prp.2014.06.017.
doi: 10.1016/j.prp.2014.06.017
pmid: 25042383
|
[16] |
Dominguezbrauer C, Thu KL, Mason JM, et al. Targeting mitosis in cancer: emerging strategies. Mol Cell 2015; 60(4):524-36. doi: 10.1016/j.molcel.2015.11.006.
doi: 10.1016/j.molcel.2015.11.006
pmid: 26590712
|
[17] |
Visconti R, Della Monica R, Grieco D. Cell cycle checkpoint in cancer: a therapeutically targetable double-edged sword. Clin Cancer Res 2016; 35(1):153. doi: 10.1186/s13046-016-0433-9.
doi: 10.1186/s13046-016-0433-9
|
[18] |
Kang X, Song C, Du X, et al. PTEN stabilizes TOP2A and regulates the DNA decatenation. Sci Rep 2016; 5(1):17873. doi: 10.1038/srep17873.
doi: 10.1038/srep17873
|
[19] |
Guillén S, Prieto L, Jiménez de Ory S, et al. Prognostic factors of a lower CD4/CD 8 ratio in long term viral suppression HIV infected children. PloS One 2019; 14(8):e0220552. doi: 10.1371/journal.pone.0220552.
doi: 10.1371/journal.pone.0220552
|
[20] |
Schmidt ME. Identification of novel respiratory syncytial virus CD4 and CD8 T cell epitopes in C57BL/6 mice. Immunohorizons 2019; 3(1):1-12. doi: 10.4049/immunohorizons.1800056.
doi: 10.4049/immunohorizons.1800056
pmid: 31356172
|
[21] |
Utama S, Patriawan P. Correlation of CD4/CD8 ratio with carotid intima-media layer thickness in HIV/AIDS patients at Sanglah General Hospital, Bali, Indonesia. Open Access Maced J Med Sci 2019; 7(11):1803-7. doi: 10.3889/oamjms.2019.479.
doi: 10.3889/oamjms.2019.479
pmid: 31316662
|